UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000017699 |
|---|---|
| Receipt number | R000020510 |
| Scientific Title | PERJETA® IV Infusion Drug use surveillance |
| Date of disclosure of the study information | 2015/05/27 |
| Last modified on | 2019/04/05 17:47:49 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
PERJETA® IV Infusion Drug use surveillance
Acronym
PERJETA® IV Infusion Drug use surveillance
Scientific Title
PERJETA® IV Infusion Drug use surveillance
Scientific Title:Acronym
PERJETA® IV Infusion Drug use surveillance
Region
| Japan |
Condition
Condition
Breast Cancer
Classification by specialty
| Endocrinology and Metabolism | Hematology and clinical oncology | Breast surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
(1) Adverse drug reactions (events of interest: febrile neutropenia, interstitial lung disease)
(2) Unknown adverse drug reactions
(3) Response rate, as assessed by the attending physician
(4) Factors thought to affect safety or efficacy
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Safety;ADR occurence
Key secondary outcomes
Efficacy;Response rate per investigator assessment
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients with breast cancer who are scheduled to start receiving PERJETA during this surveillance enrollment period.
Key exclusion criteria
No criteria
Target sample size
300
Research contact person
Name of lead principal investigator
| 1st name | Izumi |
| Middle name | |
| Last name | Kawashima |
Organization
Chugai Pharmaceutical Co., Ltd.
Division name
Real World Data Science Dept.
Zip code
103-8324
Address
1-1 Nihonbashi-muromachi 2-chome, Chuo-ku Tokyo, Japan
TEL
03-3273-0769
kawashimaizm@chugai-pharm.co.jp
Public contact
Name of contact person
| 1st name | Ayaka |
| Middle name | |
| Last name | Shimizu |
Organization
Chugai Pharmaceutical Co., Ltd.
Division name
Real World Data Science Dept.
Zip code
103-8324
Address
1-1 Nihonbashi-muromachi 2-chome, Chuo-ku Tokyo, Japan
TEL
03-3273-0905
Homepage URL
shimizuayk@chugai-pharm.co.jp
Sponsor or person
Institute
Chugai Pharmaceutical Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Chugai Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Not applicable for Drug use surveillance
Address
Not applicable for Drug use surveillance
Tel
Not applicable for Drug use surveillance
Not applicable for Drug use surveillance
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 05 | Month | 27 | Day |
Related information
URL releasing protocol
Not opened
Publication of results
Unpublished
Result
URL related to results and publications
Not opened
Number of participants that the trial has enrolled
261
Results
The incidence of adverse drug reactions (ADRs) in the 261 patients in the safety analysis set was 37.54% (98/261 patients), and there were 223 events. The most common ADRs (in 5% or more of patients) were diarrhoea (12.64%, 33/261 patients), neutrophil count decreased (7.66%, 20/261 patients), and malaise (5.74%, 15/261 patients).
Results date posted
| 2019 | Year | 04 | Month | 05 | Day |
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Patient were only wommen and a pregnant woman wasn't included. Before reaching menopause14.55 %(38/261 pts), after reaching menopause 74.71 % (195/261 pts) , and menopause came 3.06 %(8/261 examples) . By age basis, more than 15 years old, less than 65 years old, 64.75% (169/261 pts) and more than 65 years old, 35.24 % (92/261 pts) came.
Participant flow
268 patients were collected. Of these, 261 patients were included on the safety anlysis set.
Adverse events
The incidence of adverse drug reactions (ADRs) in the 261 patients in the safety analysis set was 37.54% (98/261 patients), and there were 223 events. The most common ADRs (in 5% or more of patients) were diarrhoea (12.64%, 33/261 patients), neutrophil count decreased (7.66%, 20/261 patients), and malaise (5.74%, 15/261 patients).
Outcome measures
This surveillance will collect information on the following aspects of the use of PERJETA under post-marketing conditions.
(1) Adverse drug reactions (events of interest: febrile neutropenia, interstitial lung disease)
(2) Unknown adverse drug reactions
(3) Response rate, as assessed by the attending physician
(4) Factors thought to affect safety or efficacy
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2013 | Year | 07 | Month | 26 | Day |
Date of IRB
| 2013 | Year | 07 | Month | 26 | Day |
Anticipated trial start date
| 2013 | Year | 10 | Month | 01 | Day |
Last follow-up date
| 2016 | Year | 09 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Patient baseline characteristics, Treatment history of primary disease, Concomitantdrugs, Combination therapy, Outcome, Adverse events
Management information
Registered date
| 2015 | Year | 05 | Month | 27 | Day |
Last modified on
| 2019 | Year | 04 | Month | 05 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020510
